Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
130.67
-0.78 (-0.60%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Revenue
In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth.
Revenue (ttm)
$1.30M
Revenue Growth
+550.00%
P/S Ratio
1,468.18
Revenue / Employee
$11,818
Employees
110
Market Cap
1.91B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Harmony Biosciences Holdings | 868.45M |
| Vericel | 276.26M |
| AnaptysBio | 234.60M |
| Syndax Pharmaceuticals | 172.35M |
| Mesoblast | 65.38M |
| Capricor Therapeutics | 11.13M |
| Taysha Gene Therapies | 9.77M |
INBX News
- 6 days ago - Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges - Benzinga
- 6 days ago - Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
- 7 days ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 7 days ago - Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - PRNewsWire
- 8 days ago - Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - PRNewsWire
- 5 weeks ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results - PRNewsWire
- 2 months ago - Inhibrx Announces Participation in Upcoming Scientific Conference - PRNewsWire
- 3 months ago - These 20 stocks are strong choices for momentum investors - Market Watch